Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radioactive beads aim to outperform standard liver cancer therapy

NCT ID NCT06900543

Disease control Sponsor: Chengdu New Radiomedicine Technology Co. LTD. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. The main goal is to see which treatment delays cancer growth longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NRT6003 injection (yttrium-90 carbon microspheres)
What this could lead to
If it works, this could offer a more effective, targeted treatment option for people with liver cancer that cannot be surgically removed.
What could go wrong
This is a Phase 3 trial, but it is still early to know if NRT6003 is truly better than the standard treatment. The study is small (108 people) and only in Chinese patients, so results may not apply to everyone. Risks include radiation exposure and liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Diagnosed as hepatocellular carcinoma (CNLC Ⅰa-Ⅲa) clinically, by imaging and/or pathology based on the guideline of the National Health Commission of the People's Republic of China (2024). 2. Evaluated by the investigator as not suitable for surgical resection/ablation/liver transplantation, or there is high risk for surgical resection, or the participant refuses surgical resection/ablation/liver transplantation. 3. Child-Pugh score ≤ 7. 4. Eastern Cooperative Oncology Group performance status ≤ 1. 5. Adequate organ function. Key Exclusion Criteria: 1. Imaging evidence or suspicion of extrahepatic metastases (including regional lymph node metastases). 2. Prior antitumor treatment for primary hepatocellular carcinoma. 3. Prior external radiation therapy or intra-arterial brachytherapy. 4. Liver vascular evaluation results that do not meet all the requirements of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unresectable hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unresectable hepatocellular carcinoma

Contacts and locations

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • The First Hospital Affiliated to the Army Medical University

    Chongqing, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • West China Hospital

    Chengdu, Sichuan, China

  • Xi'an International Medical Center Hospital

    Xi’an, Shanxi, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhongshan Hospital Fudan University

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.